Literature DB >> 21669574

Evaluation of hepatitis B viral replication and proteomic analysis of HepG2.2.15 cell line after knockdown of HBx.

Hai-Yang Xie1, Jun Cheng, Chun-Yang Xing, Jin-Jin Wang, Rong Su, Xu-Yong Wei, Lin Zhou, Shu-Sen Zheng.   

Abstract

BACKGROUND: Hepatitis B virus (HBV) is one of the major pathogens of human liver disease. Studies have shown that HBV X protein (HBx) plays an important role in promoting viral gene expression and replication. In this study we performed a global proteomic profiling to identify the downstream functional proteins of HBx, thereby detecting the mechanisms of action of HBx on virion replication.
METHODS: HBx in the HepG2.2.15 cell line was knocked down by the transfection of small interfering RNA (siRNA). The replication level of HBV was evaluated by microparticle enzyme immunoassay analysis of HBsAg and HBeAg in the culture supernatant, and real-time quantitative PCR analysis of HBV DNA. Two-dimensional electrophoresis combined with MALDI-TOF/TOF was performed to analyze the changes in protein expression profile after treatment with HBx siRNA.
RESULTS: Knockdown of HBx disturbed HBV replication in vitro. HBx target siRNA significantly inhibited the expression of HBsAg, HBeAg and the replication of HBV DNA. Twelve significantly changed proteins (7 upregulated and 5 downregulated) were successfully identified by MALDI-TOF/TOF using proteomics differential expression analysis after the knockdown of HBx. Among these identified proteins, HSP70 was validated by Western blotting.
CONCLUSION: The results of the study indicated the positive effect of HBx on HBV replication, and a group of downstream target proteins of HBx may be responsible for this effect.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21669574     DOI: 10.1016/s1499-3872(11)60049-0

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  5 in total

1.  Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus.

Authors:  S Zhen; L Hua; Y-H Liu; L-C Gao; J Fu; D-Y Wan; L-H Dong; H-F Song; X Gao
Journal:  Gene Ther       Date:  2015-02-05       Impact factor: 5.250

2.  Distinctive pharmacological differences between liver cancer cell lines HepG2 and Hep3B.

Authors:  Guo-Hua Qiu; Xiaojin Xie; Fang Xu; Xiaohao Shi; Yue Wang; Linhong Deng
Journal:  Cytotechnology       Date:  2014-07-08       Impact factor: 2.058

3.  Connecting rules from paired miRNA and mRNA expression data sets of HCV patients to detect both inverse and positive regulatory relationships.

Authors:  Renhua Song; Qian Liu; Tao Liu; Jinyan Li
Journal:  BMC Genomics       Date:  2015-01-21       Impact factor: 3.969

Review 4.  Advances in multi-omics research on viral hepatitis.

Authors:  Ze Xiang; Jiayuan Li; Di Lu; Xuyong Wei; Xiao Xu
Journal:  Front Microbiol       Date:  2022-09-02       Impact factor: 6.064

5.  A Tat-conjugated Peptide Nucleic Acid Tat-PNA-DR Inhibits Hepatitis B Virus Replication In Vitro and In Vivo by Targeting LTR Direct Repeats of HBV RNA.

Authors:  Zhengyang Zeng; Shisong Han; Wei Hong; Yange Lang; Fangfang Li; Yongxiang Liu; Zeyong Li; Yingliang Wu; Wenxin Li; Xianzheng Zhang; Zhijian Cao
Journal:  Mol Ther Nucleic Acids       Date:  2016-03-15       Impact factor: 10.183

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.